WOBURN, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. today said it plans to issue its fourth-quarter and year-end 2006 results after the close of the market on Wednesday, February 28, 2007. The company plans to hold a conference call the next day at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
To listen to the conference call, dial 866-770-7120 (International callers use 617-213-8065) and use the passcode 13618636. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available to interested parties through a live audio Internet broadcast at www.anikatherapeutics.com. The call will be archived and accessible on the same website shortly after the conclusion of the call. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
About Anika Therapeutics, Inc.
Headquartered in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek, and Hyvisc(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc. Anika manufactures Amvisc(TM) and Amvisc Plus(TM), HA viscoelastic products for ophthalmic surgery. It also produces STAARVISC(TM)-II, which is distributed by STAAR Surgical company and Shellgel(TM) for Cytosol Ophthalmics, Inc.
Contacts: Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Anika Therapeutics, Inc. (781) 932-6616
Anika Therapeutics, Inc.
CONTACT: Charles H. Sherwood, Ph.D., CEO, or Kevin W. Quinlan, CFO, bothof Anika Therapeutics, Inc., +1-781-932-6616
